TGFβR2×PD-1

Incyte presented promising data at ESMO 2025 for INCA33890, a TGFβR2×PD-1 bispecific antibody, showing potential efficacy in microsatellite stable (MSS) colorectal cancer with a manageable safety profile. A registrational program is planned for 2026. Also, INCB161734, a KRAS G12D inhibitor, demonstrated a favorable safety profile and clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patients. Further development plans for INCB161734 are under evaluation.